Is imatinib combined with mitoxantrone/etoposide and cytarabine an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis?
The combination of mitoxantrone/etoposide and imatinib is well tolerated, with mild nonhematologic toxicity even in older patients. Eligible patients benefit from allo-SCT after response to the induction treatment.
Preoperative elevation of the serum CRP level (> 65 mg/l) is a valuable predictor of SSI in patients undergoing appendectomy.